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To perform an automatic evaluation of the mutation, an important point is the reproducibility of the complex peak pattern. The analysis of different electrophoretic runs over 15 days confirmed the constant appearance of the peak pattern. Characteristic peaks for the wild-type and mutant alleles were defined by their retention time and height. For the sense strand (FAM), the peaks were defined by the following data points: wild-type 1, 5756; wild-type 2, 5809; mutant 1, 5736; mutant 2, 5788, and for the antisense strand (HEX): wild-type, 5867; mutant, 5738. In the antisense strand, one wild-type and one mutant peak were not considered for automatic evaluation because the two peaks partially overlapped. The variation of the peak retention time was less than Ϯ8 data points for the sense strand and less than Ϯ20 data points for the antisense strand.
The retention time of the peaks and their variations were listed in the Genotyper TM analysis software (Version 2.0; PE Applied Biosystems), and a macro was created for the analysis of the data (clear table; clear labels; select blue  lanes; and select green lanes; label category peaks with the  category's name; set up table with one category and one  lane per row; append rows to table; show the table  window; set cell row 1 column 1 to sample name; show the plot window). In the diagram, the peaks were named wild-type or mutant, and in the resulting table the summary of analysis was presented (Fig. 1) . In the table, the peaks were named wild-type for the sense and antisense single strands in the case of the homozygous presence of the wild-type allele. In the case of homozygosity of the mutation, only peaks defined as mutant were recognized; in the heterozygous state, a combination of both was present. In routine usage, the practicability and reliability of the evaluation program has been demonstrated.
The ABI 310 Genetic Analyzer has been widely distributed in clinical laboratories in the last 2 years. The main applications of this system are sequencing and fragment analysis. In our report, we showed that SSCP analysis could also be performed with high reliability by capillary electrophoresis. For the first time, the combination of SSCP analysis and automatic evaluation of the mutation has been shown, even in cases where a complex SSCP peak pattern was present. In the diagnostic DNA testing, this approach is advantageous in the analysis of small sample numbers (as little as one sample). Homocysteine (Hcy) is a sulfur amino acid formed from methionine during transmethylation. Once formed, it is either remethylated to methionine or irreversibly catabolized to cystathionine. The remethylation is catalyzed by methionine synthase (EC 2.1.1.13), which requires cobalamin as cofactor and 5-methyltetrahydrofolate as substrate (1). This explains why the fasting total homocysteine (tHcy) concentration is related to overall folate or cobalamin status and that increased tHcy has been used to diagnose deficiencies of these vitamins (2) (3) (4) .
Kinetics of Plasma

Methotrexate (MTX) is an antifolate drug that inhibits dihydrofolate reductase, thereby depleting the cells of reduced folates, including 5-methyltetrahydrofolate (5).
In cell culture studies, MTX inhibits Hcy remethylation, leading to increased Hcy export to the medium (6 -8) .
Plasma tHcy is a sensitive indicator of the antifolate effect of MTX, as demonstrated by an increased plasma tHcy concentration. The increase is maximal after ϳ2 days in psoriasis patients given only 25 mg of MTX (9) . In cancer patients receiving intermediate or high doses of MTX, there is a rapid increase in plasma tHcy within hours. However, the increased tHcy induced by MTX is normalized after rescue therapy with folinic acid (7, 10) .
We have previously shown that tHcy clearance in folate-deficient subjects with hyperhomocysteinemia is close to that observed in healthy individuals (11) . However, it has been suggested that folate status predominately affects concentrations of fasting, i.e., low tHcy concentrations. Therefore, the present study was undertaken to examine tHcy elimination in subjects with plasma tHcy within reference values and to investigate whether the antifolate effect of MTX had any influence on plasma clearance. This was carried out by monitoring elimination of [ 14 C]Hcy injected intravenously in a dose that did not affect basal tHcy concentrations. By this procedure, elimination kinetics of tHcy at low, fasting tHcy concentrations are obtained.
The study group comprised six male cancer patients (mean age Ϯ SD, 40 Ϯ 19 years; Table 1 14 C]Hcy (3.6 mol) in 20 mL of 250 mmol/L NaCl, pH 5, was injected within 1 min. Blood samples were collected for 24 h, and tHcy was determined (13) .
Plasma samples were reduced, derivatized, and quantified according to a slight modification of an automated assay for tHcy (13) 
, water (2100 L), and 25 mmol/L monobromobimane (60 L). The derivatization was stopped after 3 min by adding 210 L of glacial acetic acid. The Hcy-bimane adduct was separated and quantitated using reversed-phase chromatography as previously described (13) . For each plasma sample, six consecutive injections (each 400 L) were performed, and the eluate containing the labeled Hcy adduct was collected and pooled. The pooled eluate was evaporated to dryness and dissolved in water and scintillation fluid; the radioactivity was determined by scintillation counting (Packard Tri-Carb 300, United Technologies).
Serum cobalamin and serum folate were determined as reported elsewhere (12) .
The elimination of tHcy after intravenous injection obeys first order kinetics and is consistent with a twocompartment model (14) . However, for simplicity and comparison with our previous studies (11, 12, 15) , the elimination rate constant (k e ) and half-life (T 1/2 ) were calculated by linear regression of the terminal, linear part (2-6 h) of the log-transformed concentration vs time curve (15) . The kinetic variables were calculated using KaleidaGraph TM , Ver. 2.1.3 for Macintosh (Synergy Software). The time course for tHcy was also analyzed by the program PCNONLIN, Ver. 4.0 (Statistical Consultants Inc.) based on the Akaike's information criterion (16) for the best curve fit. The T 1/2 obtained by these two methods differed by Ͻ20% in most patients. The formulas used (17) for the calculations are given elsewhere (12) .
The results are given as mean and SD. Comparison of paired data was performed using the Wilcoxon signedrank test, and unpaired values were compared using the Mann-Whitney U-test.
The elimination kinetics of plasma tHcy were investigated in six cancer patients on two occasions, before and during HD-MTX treatment. Patient characteristics and blood indicators obtained immediately before each investigation are listed in Table 1 . All patients had serum folate and cobalamin above the reference ranges and serum creatinine concentrations within reference values. tHcy concentrations were 8.6 Ϯ 2.7 mol/L and 9.7 Ϯ 6.2 mol/L before the first (ϪMTX) and second studies (ϩMTX), respectively (Table 1) .
Within the first 15 min after the injection of the [ 14 C]Hcy tracer, there was essentially no change in tHcy (Ͻ1 mol/L). Thus, this test condition does not influence the tHcy concentration and therefore allows the assessment of plasma tHcy elimination kinetics at low, fasting concentrations. In contrast, the standard dose of unlabeled Hcy used for the Hcy loading test causes a 60 -100 mol/L increase in plasma tHcy (11, 12, 15, 18) . Plasma tHcy remained essentially stable for 24 h in the absence of MTX. Only a minor increase of 12.7% Ϯ 9.3% (1.1 Ϯ 0.8 mol/L) was observed 8 h after the injection, a diurnal change that is in the same range as previously reported in healthy individuals (18) . In contrast, there was a variable but substantial increase in tHcy in patients after MTX infusion, reaching a maximum of 49.3% Ϯ 61.6% (3.0 Ϯ 2.4 mol/L) after 12 h, demonstrating the antifolate effect of MTX. Similar effects on plasma tHcy has been reported previously (10, 19, 20) .
In the absence of MTX, the plasma T 1/2 was 2.6 Ϯ 0.5 h (k e ϭ 0.27 Ϯ 0.03), corresponding to a clearance of 78 Ϯ 10 mL/min. Plasma tHcy kinetics showed no consistent changes in response to HD-MTX. The mean differences in T 1/2 and clearance between the two occasions were 13.3% Ϯ 17.5% and Ϫ4.1% Ϯ 10.4%, respectively (P Ͼ0.05; Fig. 1 and Table 1) .
From these data, the following conclusions can be made: (a) the plasma tHcy kinetics are not affected by HD-MTX and thereby folate status, as previously demonstrated by Hcy loading in folate-deficient subjects (11); and (b) the kinetics are similar albeit slightly more rapid than observed during Hcy loading (T 1/2 ϭ 2.6 vs 3.7 h; P ϭ 0.008) (12) . These results verify that peroral Hcy loading is an adequate procedure for the assessment of Hcy turnover in plasma. 
